Xero's stock has taken a beating over the past week, sliding 15% in just five trading sessions. The cloud-accounting software giant closed at A$68.79 on Thursday, down 4% on the day, marking its fifth consecutive decline. This sharp selloff has left investors questioning whether the shares, now significantly cheaper than a year ago, are finally a bargain or if more pain lies ahead.
A Valuation Reset, Not a Guidance Cut
The recent slide is not tied to any new earnings warning. Xero's management reaffirmed its fiscal 2027 guidance at the annual meeting on August 27. Chair David Thodey acknowledged the broader rerating of software stocks and the market's focus on returns from the Melio acquisition. The board itself framed the share-price decline as a test of valuation and acquisition returns, not a mystery.
From a closing price of A$80.71 on September 3, XRO has fallen every session since. The stock is now about 19.7% below its August 28 close of A$85.64 and a staggering 58.6% beneath its 52-week high of A$166. Thursday's intraday low of A$68.68 puts the stock just 12% above its 52-week low of A$61.45.
Growth Story Intact, but Margin Pressures Loom
Despite the share-price slump, Xero's fiscal 2026 results were robust. Operating revenue surged 31% to NZ$2.753 billion, with organic revenue up 21% (19% in constant currency). Customer numbers grew 11% to 4.92 million, and average revenue per customer climbed 23% to NZ$55.44. Annualized monthly recurring revenue jumped 37% to NZ$3.273 billion.
Free cash flow rose 9% to NZ$554 million, a 20.1% margin, even as Xero absorbed Melio-related costs. Adjusted EBITDA increased 18% to NZ$757 million. However, reported net profit fell 27% to NZ$167 million, and operating income dropped 13%, highlighting the drag from the acquisition.
For fiscal 2027, Xero guides to revenue of NZ$3.62 billion to NZ$3.73 billion and adjusted EBITDA of NZ$860 million to NZ$920 million. This implies 31-35% revenue growth but only 14-21% adjusted-EBITDA growth, as the company plans up to NZ$55 million of incremental U.S. brand spending and expects a greater share of EBITDA in the second half.
Melio: The Swing Factor
Xero's acquisition of Melio for US$2.5 billion upfront, plus potential additional consideration, is the key variable. The deal was funded with a mix of an A$1.85 billion placement, stock, debt, and existing cash. At March 31, 2026, Xero reported NZ$1.95 billion of borrowings against NZ$1.93 billion of cash and short-term deposits, a significant shift from its previous net-cash position.
The strategic rationale is clear: U.S. organic revenue grew 30% in fiscal 2026, and pro-forma U.S. revenue including Melio reached NZ$530 million, up 50%. However, pro-forma gross profit increased a slower 36% to NZ$186 million, and the group's pro-forma Rule-of-40 score was 36%, versus 48.5% as reported. Melio adds speed and a larger payments opportunity but temporarily weakens the growth and free-cash-flow margin combination that software investors prize.
Analyst Targets: A Wide Range
The stock's fall below the lowest widely published analyst target does not settle the valuation debate. S&P Global consensus data from September 9 showed a median target near A$117.74, with a range from about A$76.98 to A$235.72. That enormous spread underscores the uncertainty surrounding the stock.
What Would Make Xero Genuinely Cheap?
At A$68.79, buyers no longer need Xero to recover to its old multiple to make money. They do need the company to deliver on three fronts: hold revenue within the fiscal 2027 range, show that Melio's gross profit is scaling faster than its cost base, and prevent the second-half EBITDA weighting from turning into a downgrade.
The next hard checkpoint is November 12, when Xero reports fiscal 2027 first-half results. Key metrics to watch include U.S. organic growth, Melio payments volume and gross profit, customer additions, net debt, and any change to the EBITDA guidance range.
Until then, the cleanest conclusion is narrower than 'buy the dip.' Xero's 15% five-session decline has removed a meaningful amount of optimism, and its recurring revenue plus 20% free-cash-flow margin give the rebound case substance. But with acquisition returns still unproven and most profit delivery pushed later in the year, A$68.79 is a more interesting price—not yet a low-risk one.
